Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)
Research output: Contribution to journal › Comment/debate › Research › peer-review
Documents
- Fulltext
Final published version, 175 KB, PDF document
The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.
Original language | English |
---|---|
Journal | Advances in Therapy |
Volume | 39 |
Issue number | 8 |
Pages (from-to) | 3522-3523 |
Number of pages | 2 |
ISSN | 0741-238X |
DOIs |
|
Publication status | Published - 2022 |
Bibliographical note
Publisher Copyright:
© Springer Healthcare Ltd., part of Springer Nature 2022.
ID: 327065633